Rare Autoimmune Diseases Diagnostics Market Research Report - Segmentation by Disease Type (Eosinophilic granulomatosis with polyangiitis (EGPA), Guillain-Barre syndrome, Kawasaki disease, Mixed connective tissue disease (MCTD), Myasthenia gravis, Others); Test Type (Antinuclear antibody (ANA) tests, Autoantibody tests, Complete blood count (CBC); Comprehensive metabolic panel, C-reactive protein (CRP); Erythrocyte sedimentation rate (ESR), Urinalysis); End User (Academic & Research Institutes, Diagnostic Centers, Hospitals & Clinical Laboratories, Others); and Region - Size, Share, Growth Analysis | Forecast (2024 – 2030)
Published: 2024 - January
Report Code: IM-15179
Format:
Region: Global
Chapter 1. RARE AUTOIMMUNE DISEASES DIAGNOSTICS MARKET – Scope & Methodology
1.1. Market Segmentation
1.2. Assumptions
1.3. Research Methodology
1.4. Primary Sources
1.5. Secondary Sources
Chapter 2. RARE AUTOIMMUNE DISEASES DIAGNOSTICS MARKET – Executive Summary
2.1. Market Size & Forecast – (2023 – 2030) ($M/$Bn)
2.2. Key Trends & Insights
2.3. COVID-19 Impact Analysis
2.3.1. Impact during 2023 – 2030
2.3.2. Impact on Supply – Demand
Chapter 3. RARE AUTOIMMUNE DISEASES DIAGNOSTICS MARKET – Competition Scenario
3.1. Market Share Analysis
3.2. Product Benchmarking
3.3. Competitive Strategy & Development Scenario
3.4. Competitive Pricing Analysis
3.5. Supplier - Distributor Analysis
Chapter 4. RARE AUTOIMMUNE DISEASES DIAGNOSTICS MARKET - Entry Scenario
4.1. Case Studies – Start-up/Thriving Companies
4.2. Regulatory Scenario - By Region
4.3 Customer Analysis
4.4. Porter's Five Force Model
4.4.1. Bargaining Power of Suppliers
4.4.2. Bargaining Powers of Customers
4.4.3. Threat of New Entrants
4.4.4. Rivalry among Existing Players
4.4.5. Threat of Substitutes
Chapter 5. RARE AUTOIMMUNE DISEASES DIAGNOSTICS MARKET - Landscape
5.1. Value Chain Analysis – Key Stakeholders Impact Analysis
5.2. Market Drivers
5.3. Market Restraints/Challenges
5.4. Market Opportunities
Chapter 6. RARE AUTOIMMUNE DISEASES DIAGNOSTICS MARKET - By Disease Type
6.1. Eosinophilic granulomatosis with polyangiitis (EGPA)
6.2. Guillain-Barre syndrome
6.3. Kawasaki disease
6.4. Mixed connective tissue disease (MCTD)
6.5. Myasthenia gravis
6.6. Others
Chapter 7. RARE AUTOIMMUNE DISEASES DIAGNOSTICS MARKET - By Test Type
7.1. Antinuclear antibody (ANA) tests
7.2. Autoantibody tests
7.3. Complete blood count (CBC)
7.4. Comprehensive metabolic panel
7.5. C-reactive protein (CRP)
7.6. Erythrocyte sedimentation rate (ESR)
7.7. Urinalysis
Chapter 8. RARE AUTOIMMUNE DISEASES DIAGNOSTICS MARKET - By End User
8.1. Academic & Research Institutions
8.2.Diagnostic Centers
8.3. Hospitals & Clinical Laboratories
8.4. Others
Chapter 9. RARE AUTOIMMUNE DISEASES DIAGNOSTICS MARKET – By Region
9.1. North America
9.2. Europe
9.3.The Asia Pacific
9.4.Latin America
9.5. Middle-East and Africa
Chapter 10. RARE AUTOIMMUNE DISEASES DIAGNOSTICS MARKET– Company Profiles – (Overview, Product Portfolio, Financials, Developments)
10.1. Thermo Fisher Scientific Inc. (United States)
10.2. Danaher Corporation (United States)
10.3. Abbott Laboratories (United States)
10.4. F. Hoffmann-La Roche AG (Switzerland)
10.5. Siemens Healthineers (Germany)
10.6. bioMérieux SA (France)
10.7. Bio-Rad Laboratories, Inc. (United States)
10.8. Trinity Biotech plc (Ireland)
10.9. Seramun Diagnostica GmbH (Germany)
10.10. Quest Diagnostics (United States)
Download Sample
Choose License Type
2850
5250
4500
1800
Frequently Asked Questions
Global Rare Autoimmune Diseases Diagnostics Market is estimated to be worth USD 1.21 Billion in 2022 and is projected to reach a value of USD 2.39 Billion by 2030, growing at a CAGR of 8.9% during the forecast period 2023-2030.
The Global Rare Autoimmune Diseases Diagnostics Market Drivers are the increasing government and non-profit organization initiatives regarding rare autoimmune diseases and the growing demand for novel and effective diagnostic techniques.
Based on the Disease Type, the Global Rare Autoimmune Diseases Diagnostics Market is segmented into Eosinophilic granulomatosis with polyangiitis (EGPA), Guillain-Barre syndrome, Kawasaki disease, Mixed connective tissue disease (MCTD), Myasthenia gravis, and Others.
The United States is the most dominating country in the region of North America for the Global Rare Autoimmune Diseases Diagnostics Market.
Thermo Fisher Scientific Inc., Danaher Corporation, and Abbott Laboratories are the leading players in the Global Rare Autoimmune Diseases Diagnostics Market.
